source
- Merck's sac-TMT shows promise in Chinese Phase 3 lung cancer trial, may replace chemoMerck and its Chinese partner Kelun-Biotech reported that the antibody-drug conjugate sac-TMT slowed disease progression better than a standard chemotherapy regimen in a Phase 3 trial conducted in…
- FDA acting chief says two journal articles by former commissioner do not represent agency policyActing FDA Commissioner Kyle Diamantas announced that the agency is reversing its earlier position regarding two medical‑journal articles authored by former commissioner Marty Makary. The FDA now…